Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)

Yan Leyfman, BS, Erel Joffe, MDMSc, Esther Drill, PhD, Sridevi Rajeeve, MD, Andrew D. Zelenetz, MD PhD, Maria Lia Lia Palomba, Craig H. Moskowitz, Carol S. Portlock, MD, Ariela Noy, MD, Steven M. Horwitz, MD, Alison J. Moskowitz, MD, Paul A. Hamlin, MD, Matthew J Matasar, MD, Anita Kumar, MD, Gottfried R. von Keudell, MD PhD, Connie Lee Batlevi, MD PhD, Anas Younes, MD, David J. Straus, MD

Blood (2019) 134 (Supplement_1): 2826.

https://doi.org/10.1182/blood-2019-123257

Published: 2019

Journal Articles

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

Blood (2019) 133 (20): 2121–2129.

https://doi.org/10.1182/blood-2018-10-877761

Published: 2019

Includes: Supplemental data

Journal Articles

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Tsuyoshi Muta, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Yoshimasa Suetsugu, MD, Masaaki Noda, MD, Tasuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Tatsuji Mino, Ryota Imanaka, MD, Kohei Kyo, MD, Yuta Katayama, MD PhD, Shinya Katsutani, MD PhD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 5321.

https://doi.org/10.1182/blood-2018-99-116016

Published: 2018

Journal Articles

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Blood (2018) 132 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2018-99-118364

Published: 2018

Journal Articles

Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Blood (2017) 130 (Supplement 1): 654.

https://doi.org/10.1182/blood.V130.Suppl_1.654.654

Published: 2017

Journal Articles

Significant Adverse Consequences of Initial Watchful Waiting for Follicular Lymphoma Patients: A Retrospective Analysis of Patients Diagnosed in Alberta from 1994-2011

Gwynivere Davies, MDFRCPC, Sunita Ghosh, PhD P Stat, Danielle Oh, MD, Mita Manna, MD FRCPC, Anthea Peters, MSc, MD FRCPC, Colin Stewart, Douglas A. Stewart

Blood (2017) 130 (Supplement 1): 4041.

https://doi.org/10.1182/blood.V130.Suppl_1.4041.4041

Published: 2017

Journal Articles

Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue

Lucy Hui, Gottfried von Keudell, MD PhD, Rong Wang, PhD, Amer M. Zeidan, MBBS, MHS, Steven D. Gore, MD, Xiaomei Ma, PhD, Amy J. Davidoff, PhD, Scott F Huntington, MD MPH

Blood (2016) 128 (22): 1188.

https://doi.org/10.1182/blood.V128.22.1188.1188

Published: 2016

Journal Articles

Watchful Waiting As Initial Management of Advanced-Stage Follicular Lymphoma in the Rituximab Era: Analysis of the National Cancer Data Base

Jaleh Fallah, MD, Anthony G Thomas, DO, FACP, Adam J Olszewski, MD

Blood (2015) 126 (23): 2692.

https://doi.org/10.1182/blood.V126.23.2692.2692

Published: 2015

Journal Articles

Ten Percent of Newly Diagnosed CLL Patients Are Treated within the First Year of Diagnosis: Results of a Canadian Retrospective Population-Based Study

Natasha Pardy, MD, David Conrad, MDPhD, Steve Doucette, MSc, K. Sue Robinson, MD, Stephen Couban, MD, Sudeep Shivakumar, MD

Blood (2015) 126 (23): 5282.

https://doi.org/10.1182/blood.V126.23.5282.5282

Published: 2015

Journal Articles

Flying without a net in MDS

Mikkael A. Sekeres

Blood (2013) 122 (17): 2925–2926.

https://doi.org/10.1182/blood-2013-09-525444

Published: 2013

Journal Articles

Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS)

Chadi Nabhan, MD, FACP, Michelle Byrtek, PhD, Shadi Latta, MD, Keith L Dawson, MS, RN, Xiaolei Zhou, MS, Brian K Link, MD, Jonathan W. Friedberg, MD, James R Cerhan, MD, PhD, Christopher R. Flowers, MD

Blood (2012) 120 (21): 3708.

https://doi.org/10.1182/blood.V120.21.3708.3708

Published: 2012

Journal Articles

A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States

Loretta Nastoupil, MD, Rajni Sinha, MD, MRCP, Michelle Byrtek, PhD, Michael Taylor, PharmD, PhD, James R Cerhan, MD, PhD, Jonathan Friedberg, MD, Brian K Link, MD, Ryan M Ziemiecki, MS, Jamie H. Hirata, PharmD, Christopher R Flowers, MD

Blood (2011) 118 (21): 97.

https://doi.org/10.1182/blood.V118.21.97.97

Published: 2011

Journal Articles

Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)

Rajni Sinha, MD, MRCP, Michelle Byrtek, PhD, Nutan J. DeJoubner, MD, Ajay K. Nooka, MD, MPH, FACP, Michael Taylor, PharmD, PhD, James R Cerhan, MD, PhD, Jonathan Friedberg, MD, Ryan M Ziemiecki, MS, Jamie H. Hirata, PharmD, Brian K Link, MD, Christopher R Flowers, MD

Blood (2011) 118 (21): 775.

https://doi.org/10.1182/blood.V118.21.775.775

Published: 2011

Journal Articles

Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.

Marco Gerlinger, MD, Janet Matthews, Andy Davies, T. Andrew Lister, Silvia Montoto, MD, Ama Z S Rohatiner, MD

Blood (2008) 112 (11): 3251.

https://doi.org/10.1182/blood.V112.11.3251.3251

Published: 2008

Journal Articles

Characteristics of Patients with Stage I Follicular Lymphoma (FL) Selected for Watchful Waiting (WW) in the US: Report from the National LymphoCare Study (NLCS).

Jonathan W. Friedberg, Elaine Wong, Michael Taylor, Ming Lin, Mohamed Darif, Hildy Dillon

Blood (2007) 110 (11): 3315.

https://doi.org/10.1182/blood.V110.11.3315.3315

Published: 2007

Journal Articles

Treatment Situation for Newly Diagnosed Multiple Myeloma (MM) Patients in Germany (GER)- First Results from a Representative Multicentre Treatment Survey.

Mathias R.F. Freund, W. Knauf, H. Goldschmidt, H. Einsele, M. R. Nowrousian, W. E. Berdel, W. Poenisch, C. Straka, L. Kellermann, S. Bammer, R. Angermund

Blood (2005) 106 (11): 5158.

https://doi.org/10.1182/blood.V106.11.5158.5158

Published: 2005

Journal Articles

Risk and Clinical Implications of Transformation of Follicular Lymphoma (FL) to Diffuse Large Cell B-Cell Lymphoma (tFL).

Silvia Montoto, Andrew J. Davies, Janet Matthews, Maria Calaminici, Andrew J. Norton, John Amess, Sarah Vinnicombe, Ama Z.S. Rohatiner, Andrew Lister

Blood (2005) 106 (11): 602.

https://doi.org/10.1182/blood.V106.11.602.602

Published: 2005

NARROW

Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Significant Adverse Consequences of Initial Watchful Waiting for Follicular Lymphoma Patients: A Retrospective Analysis of Patients Diagnosed in Alberta from 1994-2011

Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue

Watchful Waiting As Initial Management of Advanced-Stage Follicular Lymphoma in the Rituximab Era: Analysis of the National Cancer Data Base

Ten Percent of Newly Diagnosed CLL Patients Are Treated within the First Year of Diagnosis: Results of a Canadian Retrospective Population-Based Study

Flying without a net in MDS

Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS)

A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States

Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)

Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.

Characteristics of Patients with Stage I Follicular Lymphoma (FL) Selected for Watchful Waiting (WW) in the US: Report from the National LymphoCare Study (NLCS).

Treatment Situation for Newly Diagnosed Multiple Myeloma (MM) Patients in Germany (GER)- First Results from a Representative Multicentre Treatment Survey.

Risk and Clinical Implications of Transformation of Follicular Lymphoma (FL) to Diffuse Large Cell B-Cell Lymphoma (tFL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only